Promente Clinical Research Center
KOASTAL-3 clinical trial
Study completed — recruitment closed.
Study information
KOASTAL-3 was conducted by Neumora Therapeutics under protocol NMRA-335140-303 (NCT06058039). It evaluated an investigational molecule in people with depression.
ClinicalTrials.gov lists the study as completed, with an actual completion date of 11 June 2026. This status was checked on 24 July 2026.
Archived eligibility information
The study was intended for patients diagnosed with depression who met its protocol criteria. Promente is no longer accepting applications for KOASTAL-3.